JP4562911B2 - 遅発性ジスキネジア及び他の運動障害の治療方法 - Google Patents
遅発性ジスキネジア及び他の運動障害の治療方法 Download PDFInfo
- Publication number
- JP4562911B2 JP4562911B2 JP2000539837A JP2000539837A JP4562911B2 JP 4562911 B2 JP4562911 B2 JP 4562911B2 JP 2000539837 A JP2000539837 A JP 2000539837A JP 2000539837 A JP2000539837 A JP 2000539837A JP 4562911 B2 JP4562911 B2 JP 4562911B2
- Authority
- JP
- Japan
- Prior art keywords
- acamprosate
- magnesium
- treatment
- memantine
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000016285 Movement disease Diseases 0.000 title claims description 125
- 206010043118 Tardive Dyskinesia Diseases 0.000 title description 36
- 238000000034 method Methods 0.000 title description 17
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims description 192
- 229960004047 acamprosate Drugs 0.000 claims description 184
- 238000011282 treatment Methods 0.000 claims description 148
- 208000012661 Dyskinesia Diseases 0.000 claims description 134
- 239000011777 magnesium Substances 0.000 claims description 118
- 229910052749 magnesium Inorganic materials 0.000 claims description 117
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 108
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 48
- 208000016620 Tourette disease Diseases 0.000 claims description 48
- 230000033001 locomotion Effects 0.000 claims description 46
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 31
- 208000016686 tic disease Diseases 0.000 claims description 30
- 208000018737 Parkinson disease Diseases 0.000 claims description 19
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 11
- -1 calcium N- acetylhomopiperazine Chemical compound 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 8
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 8
- 229960004502 levodopa Drugs 0.000 claims description 8
- 239000013522 chelant Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 239000000395 magnesium oxide Substances 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 139
- 229960004640 memantine Drugs 0.000 description 136
- 239000003814 drug Substances 0.000 description 133
- 229940091250 magnesium supplement Drugs 0.000 description 120
- 229940079593 drug Drugs 0.000 description 96
- 208000014094 Dystonic disease Diseases 0.000 description 87
- 206010005159 blepharospasm Diseases 0.000 description 66
- 230000000744 blepharospasm Effects 0.000 description 66
- 230000000694 effects Effects 0.000 description 65
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 63
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 47
- 201000002904 focal dystonia Diseases 0.000 description 47
- 229930195712 glutamate Natural products 0.000 description 47
- 208000024891 symptom Diseases 0.000 description 43
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 42
- 229960001985 dextromethorphan Drugs 0.000 description 38
- 208000010118 dystonia Diseases 0.000 description 37
- 208000015592 Involuntary movements Diseases 0.000 description 36
- 230000005540 biological transmission Effects 0.000 description 33
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 31
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 31
- 230000002354 daily effect Effects 0.000 description 30
- 239000003176 neuroleptic agent Substances 0.000 description 30
- 229940124597 therapeutic agent Drugs 0.000 description 30
- 230000005062 synaptic transmission Effects 0.000 description 28
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 28
- 230000006872 improvement Effects 0.000 description 26
- 230000000701 neuroleptic effect Effects 0.000 description 23
- 230000004044 response Effects 0.000 description 22
- 230000001225 therapeutic effect Effects 0.000 description 22
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 21
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 21
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 208000010877 cognitive disease Diseases 0.000 description 19
- 208000019352 Blepharospasm-oromandibular dystonia syndrome Diseases 0.000 description 18
- 201000005190 Meige syndrome Diseases 0.000 description 18
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 18
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 18
- 230000003285 pharmacodynamic effect Effects 0.000 description 18
- 230000008901 benefit Effects 0.000 description 17
- 230000003111 delayed effect Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 229940002612 prodrug Drugs 0.000 description 17
- 239000000651 prodrug Substances 0.000 description 17
- 208000028698 Cognitive impairment Diseases 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 208000008167 Magnesium Deficiency Diseases 0.000 description 15
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 15
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 15
- 235000004764 magnesium deficiency Nutrition 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 230000015654 memory Effects 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 239000006187 pill Substances 0.000 description 12
- 229960003080 taurine Drugs 0.000 description 12
- 108030001720 Bontoxilysin Proteins 0.000 description 11
- 229940053031 botulinum toxin Drugs 0.000 description 11
- 210000000744 eyelid Anatomy 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 10
- 102000004300 GABA-A Receptors Human genes 0.000 description 10
- 108090000839 GABA-A Receptors Proteins 0.000 description 10
- 125000003047 N-acetyl group Chemical class 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 10
- 159000000003 magnesium salts Chemical class 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 208000007101 Muscle Cramp Diseases 0.000 description 9
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 9
- 208000005392 Spasm Diseases 0.000 description 9
- 208000008234 Tics Diseases 0.000 description 9
- 230000006399 behavior Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 9
- 238000009140 magnesium supplementation Methods 0.000 description 9
- 201000000980 schizophrenia Diseases 0.000 description 9
- 206010008748 Chorea Diseases 0.000 description 8
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 8
- 206010044074 Torticollis Diseases 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 208000012601 choreatic disease Diseases 0.000 description 8
- 230000003920 cognitive function Effects 0.000 description 8
- 229940052760 dopamine agonists Drugs 0.000 description 8
- 210000000609 ganglia Anatomy 0.000 description 8
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 7
- 102000015554 Dopamine receptor Human genes 0.000 description 7
- 108050004812 Dopamine receptor Proteins 0.000 description 7
- 102000018899 Glutamate Receptors Human genes 0.000 description 7
- 108010027915 Glutamate Receptors Proteins 0.000 description 7
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 7
- 208000028017 Psychotic disease Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000003492 excitotoxic effect Effects 0.000 description 7
- 239000003825 glutamate receptor antagonist Substances 0.000 description 7
- 230000001660 hyperkinetic effect Effects 0.000 description 7
- 208000018197 inherited torticollis Diseases 0.000 description 7
- 229910001425 magnesium ion Inorganic materials 0.000 description 7
- 230000007310 pathophysiology Effects 0.000 description 7
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 6
- 239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 description 6
- 208000007848 Alcoholism Diseases 0.000 description 6
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 6
- 208000020925 Bipolar disease Diseases 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 201000007930 alcohol dependence Diseases 0.000 description 6
- 229960000794 baclofen Drugs 0.000 description 6
- 230000019771 cognition Effects 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 238000010855 neuropsychological testing Methods 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- 229960000715 nimodipine Drugs 0.000 description 6
- 230000001242 postsynaptic effect Effects 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 229940122459 Glutamate antagonist Drugs 0.000 description 5
- 208000023105 Huntington disease Diseases 0.000 description 5
- 208000019430 Motor disease Diseases 0.000 description 5
- 208000013716 Motor tics Diseases 0.000 description 5
- 208000027089 Parkinsonian disease Diseases 0.000 description 5
- 206010034010 Parkinsonism Diseases 0.000 description 5
- 208000013142 Writer cramp Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 229940035678 anti-parkinson drug Drugs 0.000 description 5
- 229940049706 benzodiazepine Drugs 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 231100000318 excitotoxic Toxicity 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 201000002865 focal hand dystonia Diseases 0.000 description 5
- 208000013403 hyperactivity Diseases 0.000 description 5
- 230000001788 irregular Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000001577 neostriatum Anatomy 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000000324 neuroprotective effect Effects 0.000 description 5
- 230000036963 noncompetitive effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000001148 spastic effect Effects 0.000 description 5
- 229940126703 systemic medication Drugs 0.000 description 5
- 210000001364 upper extremity Anatomy 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 241000238876 Acari Species 0.000 description 4
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 4
- 229960003805 amantadine Drugs 0.000 description 4
- 239000000939 antiparkinson agent Substances 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 150000001557 benzodiazepines Chemical class 0.000 description 4
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 4
- 229960003120 clonazepam Drugs 0.000 description 4
- 229960002896 clonidine Drugs 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000004424 eye movement Effects 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000004112 neuroprotection Effects 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 3
- 206010013952 Dysphonia Diseases 0.000 description 3
- 229940121869 GABA A receptor agonist Drugs 0.000 description 3
- 102000005915 GABA Receptors Human genes 0.000 description 3
- 108010005551 GABA Receptors Proteins 0.000 description 3
- 229940121909 GABA receptor agonist Drugs 0.000 description 3
- 206010061991 Grimacing Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 208000003217 Tetany Diseases 0.000 description 3
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000028752 abnormal posture Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 229960004538 alprazolam Drugs 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 229960004205 carbidopa Drugs 0.000 description 3
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000002920 convulsive effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000003518 presynaptic effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 230000001020 rhythmical effect Effects 0.000 description 3
- 229960001534 risperidone Drugs 0.000 description 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 3
- 230000000698 schizophrenic effect Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229960005333 tetrabenazine Drugs 0.000 description 3
- 229960001032 trihexyphenidyl Drugs 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 206010049119 Emotional distress Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000000269 Hyperkinesis Diseases 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 229960002519 amoxapine Drugs 0.000 description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000648 anti-parkinson Effects 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 description 2
- 230000004397 blinking Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 2
- 229960002495 buspirone Drugs 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229940047608 chelated magnesium Drugs 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 2
- 231100000063 excitotoxicity Toxicity 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- 230000006959 non-competitive inhibition Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 229960004851 pergolide Drugs 0.000 description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 2
- 230000008288 physiological mechanism Effects 0.000 description 2
- 229960003089 pramipexole Drugs 0.000 description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KYZWKYWGQFCRGN-OASOTCBPSA-N (2s)-2-aminopentanedioic acid;(2r)-2-(methylamino)butanedioic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O KYZWKYWGQFCRGN-OASOTCBPSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 101150091111 ACAN gene Proteins 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006354 Congenital Nystagmus Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 101000953562 Dendroaspis angusticeps Kunitz-type serine protease inhibitor homolog calcicludine Proteins 0.000 description 1
- 101000723297 Dendroaspis polylepis polylepis Calciseptin Proteins 0.000 description 1
- 239000012848 Dextrorphan Substances 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000019749 Eye movement disease Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229940127307 Noncompetitive NMDA Receptor Antagonists Drugs 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 206010036086 Polymenorrhoea Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000033754 Rare dystonia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009042 allosteric modification Effects 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000011952 auditory verbal learning test Methods 0.000 description 1
- 208000018300 basal ganglia disease Diseases 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 229940058898 campral Drugs 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 231100000867 compulsive behavior Toxicity 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical class C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 description 1
- 229950006878 dextrorphan Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002825 dopamine reuptake Effects 0.000 description 1
- 230000000142 dyskinetic effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000009540 excitatory neurotransmission Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000000193 eyeblink Effects 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000031477 focal task-specific dystonia Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 208000028780 ocular motility disease Diseases 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000002226 simultaneous effect Effects 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 229940084765 timolol ophthalmic solution Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012034 trail making test Methods 0.000 description 1
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/006,641 US5952389A (en) | 1998-01-13 | 1998-01-13 | Methods of treating tardive dyskinesia and other movement disorders |
| US09/006,641 | 1998-01-13 | ||
| US09/193,892 | 1998-11-18 | ||
| US09/193,892 US6294583B1 (en) | 1998-01-13 | 1998-11-18 | Methods of treating tardive dyskinesia and other movement disorders |
| US09/224,829 US6057373A (en) | 1997-05-22 | 1999-01-04 | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
| US09/224,829 | 1999-01-04 | ||
| PCT/US1999/000144 WO1999036064A2 (en) | 1998-01-13 | 1999-01-13 | Methods of treating tardive dyskinesia and other movement disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002509104A JP2002509104A (ja) | 2002-03-26 |
| JP2002509104A5 JP2002509104A5 (enExample) | 2006-03-09 |
| JP4562911B2 true JP4562911B2 (ja) | 2010-10-13 |
Family
ID=27358163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000539837A Expired - Lifetime JP4562911B2 (ja) | 1998-01-13 | 1999-01-13 | 遅発性ジスキネジア及び他の運動障害の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1047436B1 (enExample) |
| JP (1) | JP4562911B2 (enExample) |
| CN (1) | CN1293573A (enExample) |
| AU (1) | AU765522B2 (enExample) |
| CA (1) | CA2318095C (enExample) |
| WO (1) | WO1999036064A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391922B1 (en) * | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| DE19830201A1 (de) * | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Mittel mit antidepressiver Wirkung |
| WO2001008670A2 (en) * | 1999-07-29 | 2001-02-08 | Interneuron Pharmaceuticals, Inc. | Methods and compositions for alleviating stuttering |
| US20050192220A1 (en) * | 2001-02-05 | 2005-09-01 | Gevys Pharmaceuticas Ltd. | Composition and method for potentiating drugs |
| AUPR625901A0 (en) * | 2001-07-10 | 2001-08-02 | Mcgregor, Neil | A method for treatment and/or prophylaxis |
| JP2005518411A (ja) * | 2002-01-16 | 2005-06-23 | エンド ファーマシューティカルズ インコーポレーテッド | 中枢神経系の障害を治療する製薬組成物及び方法 |
| AU2003213009A1 (en) * | 2002-02-12 | 2003-09-04 | Cypress Bioscience, Inc. | Methods of treating attention deficit/hyperactivity disorder (adhd) |
| US7456224B2 (en) | 2004-04-05 | 2008-11-25 | Forest Laboratories Holdings, Ltd. | Method for treating autism |
| CA2576232C (en) * | 2004-05-14 | 2009-10-27 | Green Cross Corp. | Neuroprotective properties of dextrorotatory morphinans |
| TW200626160A (en) * | 2004-09-23 | 2006-08-01 | Merz Pharma Gmbh & Co Kgaa | Memantine for the treatment of childhood behavioral disorders |
| BRPI0518483A2 (pt) * | 2004-11-23 | 2008-11-18 | Neuromolecular Pharmaceuticals Inc | composiÇço compreendendo uma matriz ou revestimento de liberaÇço controlada e um antagonista de receptor de nmda, mÉtodo para administraÇço de tal antagonista de nmda a um paciente |
| EA200800663A1 (ru) * | 2005-09-16 | 2008-10-30 | Сириусайенс Аб | Способ и средство профилактики и лечения нарушенного дыхания во время сна |
| SG10201502642TA (en) | 2006-10-12 | 2015-05-28 | Bhi Ltd Partnership | Methods, Compounds, Compositions And Vehicles For Delivering 3-Amino-1-Propanesulfonic Acid |
| CN104379138B (zh) * | 2011-12-02 | 2021-12-07 | 思康脑侒股份有限公司 | 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 |
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| CA2914365C (en) * | 2013-06-05 | 2022-03-15 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| PL3160464T3 (pl) * | 2014-06-26 | 2018-12-31 | Contera Pharma Aps | 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych |
| CN104188970A (zh) * | 2014-08-26 | 2014-12-10 | 上海交通大学医学院附属新华医院 | 右美沙芬在治疗眼睑痉挛或梅杰综合征中的应用 |
| CN108348518A (zh) * | 2015-09-08 | 2018-07-31 | 费城儿童医院 | 诊断和治疗焦虑症的方法 |
| BR112019015362A2 (pt) * | 2017-02-10 | 2020-10-20 | Asarina Pharma Ab | 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso em tratamento médico |
| CN111902138A (zh) * | 2018-01-29 | 2020-11-06 | 法奈克斯公司 | 在乙酰胆碱酯酶抑制剂治疗失去反应的患者中对阿兹海默氏病的基于巴氯芬和阿坎酸的治疗 |
| CA3137407A1 (fr) | 2019-05-16 | 2020-11-19 | Synapharm Industrial Synthesis | Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder |
| CN115184501A (zh) * | 2022-07-20 | 2022-10-14 | 中国医学科学院病原生物学研究所 | 血清代谢物组合筛查在诊断肌张力障碍症中的应用 |
| WO2025167857A1 (zh) * | 2024-02-06 | 2025-08-14 | 南京纽邦生物科技有限公司 | 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2457281A1 (fr) * | 1979-05-23 | 1980-12-19 | Meram Lab | Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee |
| US4985256A (en) * | 1988-04-27 | 1991-01-15 | Bionix Corporation | Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory |
| US5602150A (en) * | 1992-10-02 | 1997-02-11 | Research Foundation For Mental Hygiene, Inc. | Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia |
| US5356902A (en) * | 1992-11-06 | 1994-10-18 | Eli Lilly And Company | Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists |
| US5470978A (en) * | 1992-11-18 | 1995-11-28 | Eli Lilly And Company | Process and intermediates for the preparation of excitatory amino acid receptor antagonists |
| WO1996007412A1 (en) * | 1994-09-02 | 1996-03-14 | Virginia Commonwealth University | Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer |
| US5866585A (en) * | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
-
1999
- 1999-01-13 CA CA2318095A patent/CA2318095C/en not_active Expired - Lifetime
- 1999-01-13 EP EP99901314A patent/EP1047436B1/en not_active Expired - Lifetime
- 1999-01-13 WO PCT/US1999/000144 patent/WO1999036064A2/en not_active Ceased
- 1999-01-13 JP JP2000539837A patent/JP4562911B2/ja not_active Expired - Lifetime
- 1999-01-13 CN CN99803952A patent/CN1293573A/zh active Pending
- 1999-01-13 AU AU21041/99A patent/AU765522B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999036064A2 (en) | 1999-07-22 |
| EP1047436B1 (en) | 2009-10-21 |
| EP1047436A2 (en) | 2000-11-02 |
| WO1999036064A3 (en) | 1999-12-02 |
| CN1293573A (zh) | 2001-05-02 |
| CA2318095A1 (en) | 1999-07-22 |
| AU765522B2 (en) | 2003-09-18 |
| AU2104199A (en) | 1999-08-02 |
| JP2002509104A (ja) | 2002-03-26 |
| CA2318095C (en) | 2012-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4562911B2 (ja) | 遅発性ジスキネジア及び他の運動障害の治療方法 | |
| US6294583B1 (en) | Methods of treating tardive dyskinesia and other movement disorders | |
| US6057373A (en) | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists | |
| US5952389A (en) | Methods of treating tardive dyskinesia and other movement disorders | |
| DE69528773T2 (de) | Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l-phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung | |
| JP5675650B2 (ja) | 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体 | |
| JP4633262B2 (ja) | 心的外傷後ストレス障害、強迫性障害および関連する神経精神医学的障害の処置 | |
| EP0942751B1 (en) | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter | |
| US20090137565A1 (en) | Method for treatment of movement disorders | |
| EP2729216A1 (en) | Pharmaceutical composition for neurological disorders | |
| CA2444269C (en) | Treatment of disorders secondary to organic impairments | |
| AU2002258820A1 (en) | Treatment of disorders secondary to organic impairments | |
| RU2469734C2 (ru) | Лечебное средство для лечения расстройств аккомодаций "stiak" | |
| TW201117813A (en) | Role of N-2-hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury | |
| MXPA00006716A (en) | Methods of treating tardive dyskinesia and other movement disorders | |
| Vyas | 28 Pharmacology of Behavioral Disorders | |
| Delgado et al. | Treatment of mood disorders | |
| MXPA01009484A (es) | Tratamiento de trastorno de estres post-traumatico, trastorno obsesivo-compulsivo y trastornos neuropsiquiatricos relacionados | |
| UA98027C2 (uk) | Комплект для лікування розладів акомодації |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060113 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090324 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090624 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090624 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090701 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090724 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090731 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090824 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090831 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100308 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100315 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100608 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100713 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100728 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130806 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |